Natixis Advisors L.P. Trims Stock Position in Koninklijke Philips (NYSE:PHG)

Natixis Advisors L.P. decreased its position in Koninklijke Philips (NYSE:PHG) by 6.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 838,201 shares of the technology company’s stock after selling 53,060 shares during the quarter. Natixis Advisors L.P. owned about 0.09% of Koninklijke Philips worth $19,555,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. First Trust Direct Indexing L.P. increased its stake in shares of Koninklijke Philips by 30.3% during the 4th quarter. First Trust Direct Indexing L.P. now owns 81,456 shares of the technology company’s stock valued at $1,900,000 after acquiring an additional 18,942 shares during the last quarter. Intrust Bank NA acquired a new position in shares of Koninklijke Philips during the 4th quarter valued at about $253,000. Russell Investments Group Ltd. increased its stake in shares of Koninklijke Philips by 85.6% during the 4th quarter. Russell Investments Group Ltd. now owns 1,033,823 shares of the technology company’s stock valued at $24,119,000 after acquiring an additional 476,907 shares during the last quarter. Truist Financial Corp increased its stake in shares of Koninklijke Philips by 8.5% during the 4th quarter. Truist Financial Corp now owns 39,431 shares of the technology company’s stock valued at $920,000 after acquiring an additional 3,097 shares during the last quarter. Finally, Syon Capital LLC increased its stake in shares of Koninklijke Philips by 16.4% during the 4th quarter. Syon Capital LLC now owns 48,760 shares of the technology company’s stock valued at $1,138,000 after acquiring an additional 6,881 shares during the last quarter. Institutional investors and hedge funds own 13.67% of the company’s stock.

Analyst Upgrades and Downgrades

PHG has been the subject of a number of research analyst reports. BNP Paribas downgraded shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research note on Wednesday, February 7th. StockNews.com upgraded Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. UBS Group upgraded Koninklijke Philips from a “sell” rating to a “neutral” rating in a report on Tuesday, April 30th. Finally, JPMorgan Chase & Co. upgraded Koninklijke Philips from an “underweight” rating to a “neutral” rating in a report on Tuesday, April 30th. One analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.00.

Koninklijke Philips Stock Performance

NYSE PHG opened at $26.82 on Monday. Koninklijke Philips has a fifty-two week low of $17.75 and a fifty-two week high of $29.44. The business has a 50 day moving average price of $21.09 and a two-hundred day moving average price of $21.21. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.78 and a current ratio of 1.20.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.